Seres Therapeutics, Inc. Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax
Seres Therapeutics, Inc. (MCRB) had Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax of $104.00 thousand as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2018-05-09
- 2018-03-31: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $104.00K.
- 2017-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $145.00K.
- 2017-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $98.00K.
- 2017-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $175.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2018-03-31 | $104.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $145.00K 10-Q · filed 2018-05-09 |
| 2017-09-30 | $98.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $175.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $181.00K 10-Q · filed 2017-05-04 |
| 2016-12-31 | $206.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $113.00K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $38.00K 10-Q · filed 2016-08-11 |
| 2015-12-31 | $54.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | $82.00K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |